Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: A phase II randomized trial

Anti-Cancer Drugs

Volumn 21, Issue 6, 2010, Pages 662-668

  Zwitter, Matjaz ^a   Kovac, Viljem ^a   Rajer, Mirjana ^a   Vrankar, Martina ^a   Smrdel, Uros ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Elderly; Gemcitabine in prolonged infusion; Non small cell lung cancer; Phase II randomized clinical trial; Poor performance status

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; FEMALE; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 77953539831     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833ab7a0     Document Type: Article

References (37)

1. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001; 6 (Suppl 1):4-7.
2. Bianco V, Rozzi A, Tonini G, Santini D, Magnolfi E, Vincenzi B, et al. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study. Anticancer Res 2002; 22:3053-3056.
3. Quoix E, Breton JL, Ducoloné A, Mennecier B, Depierre A, Lemarié E, et al. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Lung Cancer 2005; 47:405-412.
4. Buccheri G, Ferrigno D. Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: a phase II study. Cancer 2000; 88:2677-2685.
5. Curran MP, Plosker GL. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs Aging 2002; 19:695-721.
6. O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:728-734.
7. Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007; 2:221-229.
8. Lin CC, Yang CH. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. Target Oncol 2009; 4:37-44.
9. D'Addario G, Felip E; ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2):ii39-ii40.
10. Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251-6266.
11. Govindan R, Garfield DH. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 2004; 31 (6 Suppl 11):27-31.
12. Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005; 16:1129-1134.
13. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 2009; 4:1148-1155.
14. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009; 45:275-280.
15. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer 2002; 38 (Suppl 2):S45-S50.
16. Hotta K, Fujiwara Y, Matsuo K, Suzuki T, Kiura K, Tabata M, et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 2007; 109:939-948. (Pubitemid 46333536)
17. Xiong JP, Feng M, Qiu F, Xu J, Tao QS, Zhang L, et al. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer 2008; 60:208-214.
18. Parikh PM, Narayanan P, Mistry RC, Agarwal JP, Pai VR, Nair R, et al. Treatment of advanced NSCLC (Stage IIIB and IV) with low dose gemcitabine and carboplatin. J Clin Oncol (ASCO Annual Meeting Proceedings) 2005; 23:7306.
19. Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K. Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs 2001; 19:101-104.
20. Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol 2005; 131:568-574.
21. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11:325-329.
22. Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24-h infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest 2003; 21:690-694.
23. Khaled H, Emara ME, Gaafar RM, Mansour O, AbdelWarith A, Zaghloul MS, et al. Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. Urol Oncol 2008; 26:133-136.
24. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 20 , 20-difluorodeoxycytidine 50-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27:258-262.
25. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-499.
26. Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999; 10:525-531. (Pubitemid 29410798)
27. Maurel J, Zorrilla M, Puertolas T, Anton A, Herrero A, Artal A, et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 2001; 12:713-717.
28. Hainsworth JD, Erland JB, Barton JH, Thompson DS, Stagg MP, Bradof JE, et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer 2003; 5:33-38.
29. Weissman CH, Sandbach J, Brooker R, Vellek M, Lindquist D, Conkling P, et al. Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age r65 and performance status 2. Lung Cancer 2006; 52:313-317.
30. Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, et al. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2005; 35:188-194.
31. Kaira K, Sunaga N, Yanagitani N, Aoki H, Kawata T, Utsugi M, et al. Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer. Anti-Cancer Drugs 2008; 19:289-294.
32. Mir O, Alexandre J, Ropert S, Montheil V, Martin I, Durand J-P, et al. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. Anti-Cancer Drugs 2009; 20:105-108.
33. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leoeniewski-Kmak K, Smakal M, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:623-630.
34. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008; 26:863-869.
35. Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, et al. Gemcitabine with either paclitaxel or vinorelbine vs. paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004; 91:489-497.
36. Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, et al. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a literature-based meta-analysis. Cancer 2009; 115:1924-1931.
37. Cancer incidence in Slovenia 1976; 2006. Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia, 1980; 2009.